BRAIN Biotech and TransCode Therapeutics join forces to develop a CRISPR-derived technology platform for cancer treatment
Development of a CRISPR-derived technology platform for cancer treatment
06-Mar-2023 -
BRAIN Biotech AG announced the signing of a joint development agreement (JDA) with TransCode Therapeutics, Inc. The objective of the JDA is to co-develop a platform technology that combines a Class 2 CRISPR nuclease, the cell-killing G-dase E, developed by BRAIN Biotech's Akribion Genomics unit ...
cancer
CRISPR